GB201905810D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB201905810D0
GB201905810D0 GBGB1905810.6A GB201905810A GB201905810D0 GB 201905810 D0 GB201905810 D0 GB 201905810D0 GB 201905810 A GB201905810 A GB 201905810A GB 201905810 D0 GB201905810 D0 GB 201905810D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1905810.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Priority to GBGB1905810.6A priority Critical patent/GB201905810D0/en
Publication of GB201905810D0 publication Critical patent/GB201905810D0/en
Priority to GBGB2000955.1A priority patent/GB202000955D0/en
Priority to KR1020217037686A priority patent/KR20220018963A/ko
Priority to EP20710849.9A priority patent/EP3958974A1/en
Priority to JP2021563064A priority patent/JP7603612B2/ja
Priority to CA3137240A priority patent/CA3137240A1/en
Priority to CN202080046367.0A priority patent/CN114072206B/zh
Priority to PCT/EP2020/055741 priority patent/WO2020216513A1/en
Priority to AU2020263709A priority patent/AU2020263709A1/en
Priority to US17/604,509 priority patent/US20220211810A1/en
Priority to IL287250A priority patent/IL287250A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1905810.6A 2019-04-25 2019-04-25 Method of treatment Ceased GB201905810D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GBGB2000955.1A GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment
US17/604,509 US20220211810A1 (en) 2019-04-25 2020-03-04 Method of Treatment
JP2021563064A JP7603612B2 (ja) 2019-04-25 2020-03-04 治療法
EP20710849.9A EP3958974A1 (en) 2019-04-25 2020-03-04 Method of treatment
KR1020217037686A KR20220018963A (ko) 2019-04-25 2020-03-04 치료 방법
CA3137240A CA3137240A1 (en) 2019-04-25 2020-03-04 Method of treatment
CN202080046367.0A CN114072206B (zh) 2019-04-25 2020-03-04 治疗方法
PCT/EP2020/055741 WO2020216513A1 (en) 2019-04-25 2020-03-04 Method of treatment
AU2020263709A AU2020263709A1 (en) 2019-04-25 2020-03-04 Method of treatment
IL287250A IL287250A (en) 2019-04-25 2021-10-13 treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment

Publications (1)

Publication Number Publication Date
GB201905810D0 true GB201905810D0 (en) 2019-06-05

Family

ID=66810336

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1905810.6A Ceased GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GBGB2000955.1A Ceased GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB2000955.1A Ceased GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment

Country Status (10)

Country Link
US (1) US20220211810A1 (https=)
EP (1) EP3958974A1 (https=)
JP (1) JP7603612B2 (https=)
KR (1) KR20220018963A (https=)
CN (1) CN114072206B (https=)
AU (1) AU2020263709A1 (https=)
CA (1) CA3137240A1 (https=)
GB (2) GB201905810D0 (https=)
IL (1) IL287250A (https=)
WO (1) WO2020216513A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
AU2008228247A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
SI2173890T1 (sl) * 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP3359566A1 (en) * 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2018193120A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
US20220370556A1 (en) * 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment

Also Published As

Publication number Publication date
JP2022530068A (ja) 2022-06-27
GB202000955D0 (en) 2020-03-04
EP3958974A1 (en) 2022-03-02
US20220211810A1 (en) 2022-07-07
CN114072206A (zh) 2022-02-18
CA3137240A1 (en) 2020-10-29
AU2020263709A1 (en) 2021-12-23
JP7603612B2 (ja) 2024-12-20
WO2020216513A1 (en) 2020-10-29
IL287250A (en) 2021-12-01
CN114072206B (zh) 2024-11-08
KR20220018963A (ko) 2022-02-15

Similar Documents

Publication Publication Date Title
GB201804514D0 (en) Treatment of pyroptosis
SG11202104222TA (en) Method of treatment of biological surfaces
GB201706406D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
GB201815588D0 (en) Method of treatment
IL287210A (en) Preparations for the treatment of tumors
IL287250A (en) treatment method
IL290983A (en) Treatment methods
GB201804515D0 (en) Treatment of necroptosis
GB202005231D0 (en) Method of mimimising patient risk
GB201907305D0 (en) Treatment of conditions
PL3431656T3 (pl) Sposób obróbki kamieni tłuczniowych
SG11202105877YA (en) Method of treatment
GB201918853D0 (en) Methods of treatment
IL268111A (en) Methods of treating pain
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
GB201900942D0 (en) Methods of treatment
GB201806569D0 (en) Method of treatment
GB201804021D0 (en) Method of treatment
HK40062182A (en) Method of treatment
GB201917253D0 (en) Treatment of conditions
AU2019903303A0 (en) Method of Treatment
AU2019901742A0 (en) Method of treatment
AU2019901280A0 (en) Method of Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)